Provenance Record

Clear, well-structured News piece (646 words, within the 400-1200 range). Standard Overview / What We Know / Safety / Regulatory Path / Context / What We Don't Know structure. Every claim is inline-cited to a specific source. Appropriate clinical detail without overstatement; the 'What We Don't Know' section honestly flags immature overall-survival data and the not-yet-reached combination-arm PFS2.

Read all four captured snapshots and verified every cited claim. source-0.html.gz (GlobeNewswire ASCO detailed-data release, 200): confirms mPFS 16.5 vs 9.2, HR 0.50 (CI 0.39-0.65), ORR ~46% vs ~26%, PFS2 not reached vs 21 months (HR 0.57, CI 0.41-0.78), mean treatment duration 21.4 months, all Grade 3+ AE percentages (hypertension 29.4 vs 27.4, neutropenia 15.2 vs 15.4, ALT/AST 10.8 vs 1.4), discontinuation 7.4 vs 3.8, Wagner quote verbatim ('I am very excited about the potential for this combination and expect it will be rapidly adopted as the new standard of care for patients with second-line GIST'), and 'launch bezuclastinib later this year'. source-1.html.gz (CancerNetwork, 200): confirms NCT05208047, 413 patients randomized 1:1, n=204/209, bezuclastinib 600 mg + sunitinib 37.5 mg, mPFS 16.5 (CI 13.8-19.2) vs 9.2 (CI 7.2-11.0), HR 0.50 (CI 0.39-0.65, p<.0001), ORR 45.6 vs 25.8 (P<.0001), Grade 3+ TRAEs 71.6 vs 52.4, discontinuation 7.4, Wagner title (CMO and Medical Director of Adult Ambulatory Oncology, Dana-Farber), ASCO Annual Meeting May 30. source-2.html.gz (GlobeNewswire NDA-acceptance release, 200): confirms FDA acceptance, Priority Review, PDUFA target action date November 30 2026, 'no plan to hold an advisory committee, nor have they identified any potential review issues' verbatim, 'in both GIST and systemic mastocytosis later this year are well underway' verbatim, the selective-TKI/KIT-D816V/exon-17 description verbatim, Robbins as 'President and Chief Executive Officer of Cogent Biosciences', and the for-GIST-patients-who-received-prior-treatment-with-imatinib indication. source-4.html.gz (BioSpace, 200): confirms the verbatim quoted phrase 'First positive Phase 3 trial in second-line GIST patients in over 20 years' that backs the headline framing. source-3 (AllSci) snapshot FAILED with HTTP 403 (bot-blocked) so file is null; as a last resort I verified its three attributed claims via live WebFetch, which confirmed verbatim: 'Median PFS, assessed by blinded independent central review, was 16.5 months...', 'no new approved therapy since sunitinib's approval nearly two decades ago', and 'the first regimen to demonstrate a statistically significant PFS advantage over sunitinib monotherapy in a randomized trial in post-imatinib GIST'. The two BICR-attributed and 20-year framing claims are additionally corroborated by source-0/source-1.

No fabrications, no misattributions, no hallucinated quotes. Both direct quotes (Wagner, Robbins/company) are verbatim and correctly attributed to the GlobeNewswire releases. Numbers, patient counts, dosing, NCT id, CIs, and the Nov 30 2026 PDUFA date all trace to cited sources. The 'first positive Phase 3 in second-line GIST in over 20 years' framing is supported by BioSpace's verbatim language and AllSci's two-decades context.

APPROVE. Every cited quote, number, name and date is verified against the source snapshots; the one snapshot that failed (AllSci, 403) was confirmed live and is largely corroborated elsewhere. No bot-blocked outlets (RTTNews/OncLive/targetedonc) are relied upon. The two outstanding findings are non-blocking allowlist/bot-block warnings, not factual issues, so no corrections record is warranted. Bot-blocked allowlist warnings noted in recommendations rather than acted on.